Results: Blocking BCL2, we observed reduced proliferation and clonogenic potential of CML CD34-positive cells and this cytotoxicity was improved by combination with BCR-ABL1 inhibitor. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.